BlossomHill’s Pan-KRAS Inhibitor Sticks to the Target for 54 Hours
BlossomHill Therapeutics unveiled pan-KRAS inhibitor BH-501284 at AACR 2026 with sub-nanomolar potency.
Jeff Martin
NETRIS Got Pancreatic Cancer Data Into Nature. The Number That Matters Is 40%.
NETRIS Pharma published Phase 1b data for anti-netrin-1 antibody NP137 in pancreatic cancer in Nature.
10x Science Got $4.8M to Read Mass Spec Data Like a Biologist
10x Science raised $4.8M seed led by Initialized to automate protein characterization with AI.
Dewpoint Cut 70% of Staff. Now They’re Chasing MYC.
Dewpoint Therapeutics presents preclinical data on an oral MYC condensate modulator at AACR 2026.
Rznomics Rewrites Liver Cancer RNA. 23% Complete Response.
Rznomics shows 61.5% response rate and 23% complete responses in HCC with its RNA ribozyme platform.
GEn1E Paid Its Manufacturer in Equity. That’s the Real Story.
GEn1E Lifesciences brings on Rubicon Research as a manufacturing partner with equity and milestone-based compensation.
Medicenna Thinks They Can Figure Out IL-2. Are They Right?
Medicenna presents preclinical NHP data for MDNA113, a conditionally activated PD-1 × IL-2 bifunctional, with IND planned H2 2026.
Ray Therapeutics Pulls $125M From An All-Star Roster Of Investors
Ray Therapeutics closes an upsized $125M Series B to advance its optogenetic gene therapy for retinitis pigmentosa.
Jeff Jonas Raised $106M. Then Bought Programs From Eisai and Hansoh.
Tortugas Neuroscience launches with $106M and two in-licensed clinical-stage assets from Eisai and Hansoh.
Enara Bio Is Targeting Antigens That Come From Dark Matter
Enara Bio presented preclinical data for ENA101, a bispecific TCE targeting a dark proteome antigen.